Two new biomarkers for a type of cancer in children called neuroblastoma have been identified in a study published in the March 12, 2018 issue of Cancer Cell. The article is titled “Sense-Antisense lncRNA Pair Encoded by Locus 6p22.3 Determines Neuroblastoma Susceptibility via the USP36-CHD7-SOX9 Regulatory Axis.” The findings are expected to have immediate significance for disease prognosis, and eventually also for treatment. “There is a need for new methods of treatment for high-risk patients, and that’s where our research can lead to truly great benefits,” says Chandrasekhar Kanduri (photo), PhD, Professor of Medical Biochemistry and Cell Biology at Sahlgrenska Academy at Gothenburg University in Sweden. Neuroblastoma is the most common form of childhood cancer of the peripheral nervous system, the part of the nervous system that is not the brain or spinal cord. The disease can occur in the chest, neck, abdomen and adrenal glands and also spread to the spinal column. Symptoms may be general aches, anemia, and skeletal pains. When the disease is detected, the children are 17 months old on average and rarely over five years old. Milder variants of neuroblastoma may heal on their own in some cases, while the aggressive cases are the deadliest form of childhood cancer. Treatment is successful in less than half of these cases. Identification of high-risk patients is crucial, and this is where the new findings come in. With the support of patient data from Sweden (59 cases) and Germany (498 cases), researchers have identified two new types of RNA molecules that control the stability of tumor proteins and that, along with an already known RNA molecule, form a trio that can indicate how serious the condition of an individual patient is.
Login Or Register To Read Full Story